MoonLake Immunotherapeutics MLTX Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Eli LillyLLY

——

Oruka Therapeutics, Inc.ORKA

——

AnaptysBio, Inc.ANAB

——

Nektar TherapeuticsNKTR

——

Aurinia PharmaceuticalsAUPH

——

Kymera TherapeuticsKYMR

——

Other financials

Income statement

See full

Operating income-$70.0M-47.5%

Net income-$69.7M-74.5%

EPS (diluted)-$0.98-55.6%

Balance sheet

See full

Cash & equivalents$298.5M+9.9%

Total debt$100.8M+33.3%

Total equity$254.0M-37.7%

Total assets$400.4M-21.7%

Cash flow

See full

Operating cash flow-$66.3M-73.8%

CapEx--100%

Free cash flow-$66.3M-73.6%

Valuation

See full

Market cap$1.56B-45.9%

Enterprise value$1.36B-50.0%

Returns & leverage

See full

Return on equity-77.7%-221pp

Debt / equity0.4×+0.2×

Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MoonLake Immunotherapeutics's software and technology licenses, net?: MoonLake Immunotherapeutics (MLTX) reported software and technology licenses, net of $1.34M in Q1 2026.
How has MoonLake Immunotherapeutics's software and technology licenses, net changed year-over-year?: MoonLake Immunotherapeutics's software and technology licenses, net decreased by 20.8% year-over-year, from $1.7M to $1.34M.